ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

elebsiran

Also written as “VIR-2218”, “Elebsiran” and “BRII-835 (VIR-2218)”.

Its studies are mostly in Hepatitis B, Chronic · Hepatitis · Renal Insufficiency · Fibrosis · Hepatitis D, Chronic, led by 3 companies.

Drug pageElebsiran: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Mar 24, 202511 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vir Biotechnologyits history only84 open or runningphase 3since Mar 24, 2025Sep 11, 2018Dec 2026phase 3 · NCT07128550
Brii Biosciences20 open or runningphase 2since Aug 7, 2020Aug 7, 2020none ahead
Virion Therapeuticsits history only10 open or runningphase 1since Sep 20, 2023Sep 20, 2023none ahead

Also a collaborator on its studies: VBI Vaccines and Alnylam Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Brii Biosciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 7, 2020First study: phase 2 study in Hepatitis B, ChronicFirst studyNCT04507269 · 21 enrolled · China
  2. Feb 7, 2021Phase 2 study in Hepatitis B, ChronicNCT04749368 · 91 enrolled · Australia, China, New Zealand and more
  3. Jul 21, 2022Named elebsiranINNProposed as its International Nonproprietary Name in WHO's List 127 · before, VIR-2218

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 Brii Biosciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04749368Hepatitis B, Chronic · Australia, China, New Zealand and more2CompletedJul 4, 202391
NCT04507269Hepatitis B, Chronic · China2CompletedSep 30, 202121

How it is read

Names in the registry

  • “VIR-2218”, 7 entries
  • “Elebsiran”, 3 entries
  • “BRII-835 (VIR-2218)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.